The role of antiandrogen monotherapy in the treatment of prostate cancer.
about
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progressionLigand-specific dynamics of the androgen receptor at its response element in living cellsProstate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses.The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis.Rooster feathering, androgenic alopecia, and hormone-dependent tumor growth: what is in common?Hormonal therapy in metastatic prostate cancer: current perspectives and controversiesManagement of recurrent disease after radical prostatectomy.The physiological basis of human sexual arousal: neuroendocrine sexual asymmetry.Structure-based virtual screening and identification of a novel androgen receptor antagonist.Neurophysiology of the ejaculatory process: developing perspectives.Androgen receptor: role and novel therapeutic prospects in prostate cancer.Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects.Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments.Androgen deprivation therapy: past, present and future.New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.Chemical castration and anti-androgens induce differential gene expression in prostate cancer.New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer.KLF9, a transcription factor induced in flutamide-caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells.Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response.Permitted Daily Exposure (PDE) of the Androgen Receptor Antagonist Flutamide.Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines.Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistanceTargeting the androgen receptor in triple-negative breast cancer: current perspectives.Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily.Bicalutamide 150 mg: practical prescribing in patients with early prostate cancer.Case study: management of advanced prostate cancer with soft tissue metastases.The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases.
P2860
Q24313269-49552D31-E157-4C36-A608-31101C7F9CC2Q24681534-DC002BBA-F777-4C03-BBB0-4CBE99B3140BQ33798326-CFB48236-9276-418C-B76B-E57E1ED3B6BBQ34531624-B9200A76-61B0-4C40-AC80-F8FA362E35B3Q35234621-49E3EE45-06A4-4BD4-A261-8AFCA1657AFFQ35569303-BF46DECA-0953-41D7-878B-841752F22014Q35847642-28DE5715-8791-4F9F-999B-638FD4616DAAQ36089403-9AF24C3F-1282-4C30-93A4-0C70DBEDF1DAQ36216496-63BB1F42-7255-4E72-BC70-3FF787FF9F38Q36312860-F5937557-7C68-46AB-A85A-13A25691403DQ37256846-F18EF6DF-7DF2-49EA-9588-429E6EA73944Q37303584-A64C1A34-9FD0-456C-BB05-935C0B179DB0Q37855836-56360EB2-D005-4C5F-88F5-8566ABAE2639Q38016530-02FFD72C-7EF3-4695-A43F-7534BE0BDEBEQ38023124-1906534C-7923-4371-8493-48A89463D85AQ38326753-56370357-8544-47F2-95C1-08AEE9D1620DQ38745981-09DEADBA-7F4C-4209-9BF4-27183D7E43AEQ39003629-E30D324E-F8F7-4A7F-A793-2D9D90C35F3DQ39292683-6925A9FF-45DC-49EE-9ECF-F1C4F36FB6E1Q39407509-11DFCA11-2738-4637-9212-3A33C497A751Q39982887-24F40234-3A46-4F09-B467-9D9A2946DC47Q41314252-374944E2-7393-436E-A418-968C101DB50CQ42364449-D2C3656D-A3AC-42BD-A01A-BF017ED93646Q44956709-E7F679CE-0509-4543-8830-C38BA3DF4143Q45100344-5CBFCC9B-CD8B-42FA-98C9-CCD18C63F592Q46531728-3F2EE6CD-91C8-4FE7-9088-11948D7581ACQ46753217-C8FDF6B7-C041-41DA-99F1-0FE0B315D42BQ48724046-96700CE4-ABCF-46A0-AC91-62D679E06FCDQ49022529-B274A37B-4250-4ED5-A3B3-3428046F4C3B
P2860
The role of antiandrogen monotherapy in the treatment of prostate cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The role of antiandrogen monotherapy in the treatment of prostate cancer.
@ast
The role of antiandrogen monotherapy in the treatment of prostate cancer.
@en
The role of antiandrogen monotherapy in the treatment of prostate cancer.
@nl
type
label
The role of antiandrogen monotherapy in the treatment of prostate cancer.
@ast
The role of antiandrogen monotherapy in the treatment of prostate cancer.
@en
The role of antiandrogen monotherapy in the treatment of prostate cancer.
@nl
prefLabel
The role of antiandrogen monotherapy in the treatment of prostate cancer.
@ast
The role of antiandrogen monotherapy in the treatment of prostate cancer.
@en
The role of antiandrogen monotherapy in the treatment of prostate cancer.
@nl
P1433
P1476
The role of antiandrogen monotherapy in the treatment of prostate cancer.
@en
P2093
Anderson J
P304
P356
10.1046/J.1464-410X.2003.04026.X
P577
2003-03-01T00:00:00Z